



an Open Access Journal by MDPI

## Novel Concepts and Technologies in Vaccine Development for Emerging Pathogens

Guest Editors:

### Dr. Wildriss Viranaicken

PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France

### Dr. Grégorie Lebeau

PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France

Deadline for manuscript submissions:

**31 March 2025**

### Message from the Guest Editors

Dear Colleagues,

Vaccination remains one of the most effective strategies for preventing and controlling infectious diseases. Due to biotechnological and molecular techniques, vaccine antigen production has realized significant advancements. This Special Issue aims to compile cutting-edge research and reviews focusing on innovative methods and technologies for producing antigens used in vaccination. We invite original research articles and comprehensive reviews on the following topics: recombinant protein antigens, peptide-based vaccines, DNA and RNA vaccines, virus-like particles (VLPs) and adjuvant development.

We invite researchers and practitioners from academia and industry to submit original research articles, comprehensive reviews and insightful commentaries notably on the following topics:

- Recombinant Protein Antigens
- Peptide-Based Vaccines
- DNA and RNA Vaccines
- Virus-Like Particles (VLPs)
- Adjuvant Development



[mdpi.com/si/211753](https://mdpi.com/si/211753)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)